PRAME expression and response in early CP patients
| . | PRAME detected, no. (%) . | PRAME not detected, no. (%) . |
|---|---|---|
| Responded to imatinib | 23 (45) | 28 (55) |
| Failed imatinib | 5 (71) | 2 (29) |
| . | PRAME detected, no. (%) . | PRAME not detected, no. (%) . |
|---|---|---|
| Responded to imatinib | 23 (45) | 28 (55) |
| Failed imatinib | 5 (71) | 2 (29) |
A similar difference was observed in 58 newly diagnosed and untreated CP CML patients. The proportions of patients expressing PRAME in the imatinib mesylate (IM) responder and IM nonresponder groups were similar to the late CP patients receiving nilotinib, but did not reach statistical significance (P=.25). PRAME expression was detected in 5 (71%) of 7 patients who failed IM compared with 23 (45%) of 51 patients who responded to IM.